Περίληψη:
The purpose of this study was to evaluate the diagnostic efficacy and
safety of an intravenous injection of magnetic resonance imaging (MRI)
contrast agent, SH U 555 A, in adult patients with known focal liver
lesions. Pre- and post-contrast image sets were obtained in 19 patients
after injection of SH U 555 A as a part of a phase III clinical trial
(patients <60 kg body weight received 0.9 mL and patients >60 kg
received 1.4 mL). Three blinded readers evaluated the post-contrast
images. Blood pressure and heart rate were recorded and laboratory tests
were performed at baseline, during and immediately after the procedure,
and four and 24 hours after the MR procedure. On post-contrast MRI,
there was statistically significant improvement in diagnostic
confidence, visualization, delineation, and contrast between the lesions
and the healthy parenchyma in comparison to precontrast. Twenty more
lesions were detected on post-contrast images. The management in six
patients (31.7%) was changed after post-contrast imaging. Changes in
vital signs and laboratory tests were minimal and did not affect the
patients’ clinical condition. Only a moderate allergic reaction (diffuse
erythematous rash) was recorded. SH U 555 A is an effective and safe
contrast agent for MRI of the liver. (C) 2001 Wiley-Liss, Inc.
Συγγραφείς:
Kehagias, DT
Gouliamos, AD
Smyrniotis, V
Vlahos, LJ
